264 related articles for article (PubMed ID: 23742728)
1. Evaluating the cognitive effects of donepezil 23 mg/d in moderate and severe Alzheimer's disease: analysis of effects of baseline features on treatment response.
Sabbagh M; Cummings J; Christensen D; Doody R; Farlow M; Liu L; Mackell J; Fain R
BMC Geriatr; 2013 Jun; 13():56. PubMed ID: 23742728
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer's disease: A 24-week, randomized, double-blind study.
Farlow MR; Salloway S; Tariot PN; Yardley J; Moline ML; Wang Q; Brand-Schieber E; Zou H; Hsu T; Satlin A
Clin Ther; 2010 Jul; 32(7):1234-51. PubMed ID: 20678673
[TBL] [Abstract][Full Text] [Related]
3. Donepezil preserves cognition and global function in patients with severe Alzheimer disease.
Black SE; Doody R; Li H; McRae T; Jambor KM; Xu Y; Sun Y; Perdomo CA; Richardson S
Neurology; 2007 Jul; 69(5):459-69. PubMed ID: 17664405
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of an 8-item Severe Impairment Battery (SIB-8) vs. the full SIB in moderate to severe Alzheimer's disease patients participating in a donepezil study.
Schmitt FA; Saxton J; Ferris SH; Mackell J; Sun Y
Int J Clin Pract; 2013 Oct; 67(10):1050-6. PubMed ID: 24073978
[TBL] [Abstract][Full Text] [Related]
5. Safety and tolerability of donepezil at doses up to 20 mg/day: results from a pilot study in patients with Alzheimer's disease.
Doody RS; Corey-Bloom J; Zhang R; Li H; Ieni J; Schindler R
Drugs Aging; 2008; 25(2):163-74. PubMed ID: 18257603
[TBL] [Abstract][Full Text] [Related]
6. Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group.
Rogers SL; Doody RS; Mohs RC; Friedhoff LT
Arch Intern Med; 1998 May; 158(9):1021-31. PubMed ID: 9588436
[TBL] [Abstract][Full Text] [Related]
7. Effect of donepezil on cognition in severe Alzheimer's disease: a pooled data analysis.
Cummings J; Jones R; Wilkinson D; Lopez O; Gauthier S; Waldemar G; Zhang R; Xu Y; Sun Y; Richardson S; Mackell J
J Alzheimers Dis; 2010; 21(3):843-51. PubMed ID: 20634594
[TBL] [Abstract][Full Text] [Related]
8. Changes in regional cerebral blood flow and functional connectivity in the cholinergic pathway associated with cognitive performance in subjects with mild Alzheimer's disease after 12-week donepezil treatment.
Li W; Antuono PG; Xie C; Chen G; Jones JL; Ward BD; Franczak MB; Goveas JS; Li SJ
Neuroimage; 2012 Apr; 60(2):1083-91. PubMed ID: 22245641
[TBL] [Abstract][Full Text] [Related]
9. Functional, cognitive and behavioral effects of donepezil in patients with moderate Alzheimer's disease.
Gauthier S; Feldman H; Hecker J; Vellas B; Emir B; Subbiah P;
Curr Med Res Opin; 2002; 18(6):347-54. PubMed ID: 12442882
[TBL] [Abstract][Full Text] [Related]
10. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease.
Feldman H; Gauthier S; Hecker J; Vellas B; Subbiah P; Whalen E;
Neurology; 2001 Aug; 57(4):613-20. PubMed ID: 11524468
[TBL] [Abstract][Full Text] [Related]
11. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group.
Rogers SL; Farlow MR; Doody RS; Mohs R; Friedhoff LT
Neurology; 1998 Jan; 50(1):136-45. PubMed ID: 9443470
[TBL] [Abstract][Full Text] [Related]
12. Donepezil treatment of patients with MCI: a 48-week randomized, placebo-controlled trial.
Doody RS; Ferris SH; Salloway S; Sun Y; Goldman R; Watkins WE; Xu Y; Murthy AK
Neurology; 2009 May; 72(18):1555-61. PubMed ID: 19176895
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of donepezil in patients with Alzheimer's disease: results of a global, multinational, clinical experience study.
Boada-Rovira M; Brodaty H; Cras P; Baloyannis S; Emre M; Zhang R; Bahra R;
Drugs Aging; 2004; 21(1):43-53. PubMed ID: 14715043
[TBL] [Abstract][Full Text] [Related]
14. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting.
Tariot PN; Cummings JL; Katz IR; Mintzer J; Perdomo CA; Schwam EM; Whalen E
J Am Geriatr Soc; 2001 Dec; 49(12):1590-9. PubMed ID: 11843990
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of increasing donepezil in mild to moderate Alzheimer's disease patients who show a diminished response to 5 mg donepezil: a preliminary study.
Yatabe Y; Hashimoto M; Kaneda K; Honda K; Ogawa Y; Yuuki S; Ikeda M
Psychogeriatrics; 2013 Jun; 13(2):88-93. PubMed ID: 23909965
[TBL] [Abstract][Full Text] [Related]
16. Donepezil delays progression to AD in MCI subjects with depressive symptoms.
Lu PH; Edland SD; Teng E; Tingus K; Petersen RC; Cummings JL;
Neurology; 2009 Jun; 72(24):2115-21. PubMed ID: 19528519
[TBL] [Abstract][Full Text] [Related]
17. Donepezil in patients with severe Alzheimer's disease: double-blind, parallel-group, placebo-controlled study.
Winblad B; Kilander L; Eriksson S; Minthon L; Båtsman S; Wetterholm AL; Jansson-Blixt C; Haglund A;
Lancet; 2006 Apr; 367(9516):1057-1065. PubMed ID: 16581404
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: a subgroup analysis from a randomized, placebo-controlled trial.
Feldman H; Gauthier S; Hecker J; Vellas B; Xu Y; Ieni JR; Schwam EM;
Int J Geriatr Psychiatry; 2005 Jun; 20(6):559-69. PubMed ID: 15920715
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and Safety of Sustained Release Donepezil High Dose versus Immediate Release Donepezil Standard Dose in Japanese Patients with Severe Alzheimer's Disease: A Randomized, Double-Blind Trial.
Homma A; Atarashi H; Kubota N; Nakai K; Takase T
J Alzheimers Dis; 2016 Mar; 52(1):345-57. PubMed ID: 26967222
[TBL] [Abstract][Full Text] [Related]
20. Differential efficacy of treatment with acetylcholinesterase inhibitors in patients with mild and moderate Alzheimer's disease over a 6-month period.
López-Pousa S; Turon-Estrada A; Garre-Olmo J; Pericot-Nierga I; Lozano-Gallego M; Vilalta-Franch M; Hernández-Ferràndiz M; Morante-Muñoz V; Isern-Vila A; Gelada-Batlle E; Majó-Llopart J
Dement Geriatr Cogn Disord; 2005; 19(4):189-95. PubMed ID: 15677866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
